Abstract:In continuation of our efforts toward the discovery of potent HIV-1 NNRTIs with diverse structures, a series of novel S-DACO analogues of 6-(2-cyclohexyl-1-alkyl)-2-(2-oxo-2-phenyl-ethylsulfanyl)pyrimidin-4(3H)-ones were designed, synthesized and evaluated for their antiviral activities in MT-4 cells. Most of these new compounds showed moderate to good activities against wild type HIV-1 with IC50 values ranging from 7.55 μmol/L to 0.018 μmol/L. Among them, compound 5c was identified as the most promising inhibitor against HIV-1 replication with an IC50 = 0.018 μmol/L, CC50 = 194 μmol/L, and SI = 12791, which was much more potent than the reference drugs NVP and DLV and comparable to AZT and EFV. In addition, 5c also exhibited improved activity against double mutant HIV-1 strain RES056 compared to that of the reference drugs NVP/DLV and DB02. The preliminary structure-activity relationship (SAR) and molecular modeling studies were also discussed, which provides some useful indications for guiding the further rational design of new S-DACO analogues.

Synthesis and biological evaluation of novel dihydro-aryl/alkylsulfanyl-cyclohexylmethyl-oxopyrimidines (S-DACOs) as high active anti-HIV agents.

Structure-based linker optimization of 6-(2-cyclohexyl-1-alkyl)-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors

Synthesis and Anti-HIV-1 Activity Evaluation of 5-Alkyl-2-alkylthio-6-(arylcarbonyl or Α-Cyanoarylmethyl)-3,4-dihydropyrimidin-4(3h)-ones As Novel Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors.

Synthesis and in vitro anti-HIV evaluation of a new series of 6-arylmethyl-substituted S-DABOs as potential non-nucleoside HIV-1 reverse transcriptase inhibitors.

Anti-AIDS Agents 86. Synthesis and Anti-Hiv Evaluation of 2′,3′-Seco-3′-nor DCP and DCK Analogues

Synthesis and biological evaluation of novel piperidin-4-ol derivatives

Synthesis and Biological Evaluation of New Conformationally Restricted S-DABO Hybrids As Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase

Synthesis and Biological Evaluation of Novel 2-Arylalkylthio-5-iodine-6-substituted-benzyl-pyrimidine-4(3h)-ones As Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors.

Synthesis and Biological Evaluation of Novel N-[3-(4-phenylpip-erazin-1-yl)-propyl]-carboxamide Derivatives

Synthesis and Biological Evaluation of Novel 2-Arylalkylthio-5-iodo-6-benzyl S-DABOs As Potent Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors

5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series.

Synthesis And Biological Evaluation Of Novel 5-Alkyl-2-Arylthio-6-((3,4-Dihydroquinolin-1(2h)-Yl)Methyl)Pyrimidin-4(3 H)-Ones As Potent Non-Nucleoside Hiv-1 Reverse Transcriptase Inhibitors

Synthesis and biological evaluation of novel C5 halogen-functionalized S-DABO as potent HIV-1 non-nucleoside reverse transcriptase inhibitors

Optimization of the Antiviral Potency and Lipophilicity of Halogenated 2,6‐diarylpyridinamines As a Novel Class of HIV‐1 NNRTIS

Anti-Aids Agents 84. Synthesis and Anti-Human Immunodeficiency Virus (hiv) Activity of 2 '-Monomethyl-4-methyl- and 1 '-Thia-4-methyl-(3 ' R,4 ' R)-3 ',4 '-Di-o-(s)-camphanoyl-(+)-cis-khellactone (dck) Analogs

C6-structural optimizations of 2-aryl-1H-pyrazole-S-DABOs: From anti-HIV to anti-DENV activity

Synthesis and structure-activity relationship of novel diarylpyrimidines with hydromethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs.

Design, Synthesis and Biological Evaluation of (E)-3,4-dihydroxystyryl 4-Acylaminophenethyl Sulfone, Sulfoxide Derivatives As Dual Inhibitors of HIV-1 CCR5 and Integrase.

Design, synthesis and biological evaluation of cycloalkyl arylpyrimidines (CAPYs) as HIV-1 NNRTIs.

Design and Synthesis of a New Series of Cyclopropylamino-Linking Diarylpyrimidines As HIV Non-Nucleoside Reverse Transcriptase Inhibitors.

Dihydro-alkoxyl-benzyl-oxopyrimidine Derivatives (dabos) As Non-Nucleoside Reverse Transcriptase Inhibitors: an Update Review (2001-2011).